EUVIMEDEUVIMED entdecken
Crossref

ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity

Young Gyun Ko iD, Jongho Ham iD, Jaemoon Koh iD, Jihyun Kim iD, Han Byeol Kim iD, Doo Hyun Chung iD, Chul-Hwan Lee iD, Sung Ho Park iD, TaeSoo Kim iD, Hye Young Kim iD

Science Immunology · 2026

DOI: 10.1126/sciimmunol.adz0989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2026. Verfasst von Young Gyun Ko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University, College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Eosinophils, Interleukin-9, Immunity, Innate, Lymphocytes. Die Arbeit nennt 71 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EosinophilsInterleukin-9Immunity, InnateLymphocytesMelanomaAnimalsHumansMiceGlucocorticoid-Induced TNFR-Related ProteinMice, Inbred C57BLLung NeoplasmsMice, Knockout

Substanzen

Interleukin-9Glucocorticoid-Induced TNFR-Related Protein

Autor:innen und Institutionen

  • Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University, College of Medicine, Seoul, South Korea.
  • Department of Biomedical Sciences, BK 21 Plus Biomedical Science Project, Seoul National University, College of Medicine, Seoul, South Korea.
  • Department of Life Science, Multitasking Macrophage Research Center, Ewha Womans University, Seoul, South Korea.
  • Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
  • Laboratory of Immune Regulation, Department of Biomedical Sciences, Seoul National University, College of Medicine, Seoul, South Korea.

ORCID-Profile: Young Gyun Ko, Jongho Ham, Jaemoon Koh, Jihyun Kim, Han Byeol Kim, Doo Hyun Chung, Chul-Hwan Lee, Sung Ho Park, TaeSoo Kim, Hye Young Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Ko, Y. G., Ham, J., Koh, J., Kim, J., Kim, H. B., Chung, D. H., Lee, C. H., Park, S. H., Kim, T., & Kim, H. Y. (2026). ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity. Science Immunology. https://doi.org/10.1126/sciimmunol.adz0989

Vancouver

Ko YG, Ham J, Koh J, Kim J, Kim HB, Chung DH, et al. ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity. Science Immunology. 2026. doi:10.1126/sciimmunol.adz0989

BibTeX
@article{Ko2026,
  author = {Ko, Young Gyun and Ham, Jongho and Koh, Jaemoon and Kim, Jihyun and Kim, Han Byeol and Chung, Doo Hyun and Lee, Chul-Hwan and Park, Sung Ho and Kim, TaeSoo and Kim, Hye Young},
  title = {ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity},
  journal = {Science Immunology},
  year = {2026},
  doi = {10.1126/sciimmunol.adz0989}
}
Kostenlos starten →